However, among the 93 patients with duodenal adenocarcinoma, there were 23 patients with KRAS mutation, and they were significantly different from the 70 patients without KRAS mutation in terms of sex (P = 0.01), BRAF mutation (P < 0.01), and mucin phenotype (P = 0.01; Table 3). This evidence concerns the gene BRAF and duodenal adenocarcinoma.